Investigation of DHA Intake in Pregnant and Lactating Women in China

This is a multi-center, cross-sectional, non-interventional, observational study--an investigation carried out in 816 pregnant (pregnant week 17±2 group and pregnant week 39±2 group; 408 cases in each group) and 408 lactating women (post-natal lactation day 42±7 group) from a total of 4 sites in 3 typical areas (1 coastal regions, 2 inland regions and 1 lake regions) in China to study the correlation between DHA intake and DHA concentrations in blood and breast milk.

Study Overview

• Status: Completed
• Conditions: Nutrient Intake Disorder

Detailed Description

This is a multi-center, cross-sectional, non-interventional, observational study in 816 pregnant (gestation week 17±2 group and gestation week 39±2 group 408 cases in each group) and 408 lactating women (post-natal lactation day 42±7 group) from a total of 4 sites in 3 typical areas (1 coastal regions, 2 inland regions and 1 lake regions) in China to study the correlation between DHA intake and DHA concentrations in blood and breast milk. Investigators are mainly physicians majoring in gynaecology and obstetrics, etc. During visits, the study physician will record the patient's social demographic data, disease and relevant medication history, review her medical records, assess DHA intake by the DHA Screener, and determine DHA concentrations in erythrocyte membrane, plasma and breast milk, so as to validate the feasibility of DHA Screener as DHA intake assessment tool for determining DHA concentrations in the body.

Subjects meeting inclusion criteria and non of the exclusion criteria will be informed of relevant information of the study. Subjects should be voluntarily consent to participate in the study and sign the informed consent form.

Screening of the study is scheduled for as long as 5 months. In this study, additional examinations or other interventions are not required.

• Study Type: Observational
• Enrollment (Actual): 1254

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 40 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Female

• Sampling Method: Non-Probability Sample

Study Population

816 pregnant (pregnant week 17±2 group and pregnant week 39±2 group; 408 cases in each group) and 408 lactating women (post-natal lactation day 42±7 group)

Description

Inclusion Criteria:

PREGNANT WOMEN:

• Healthy women presenting at their week 17±2 and week 39±2 obstetric examination;
• 18-40 years of age;
• Monocyesis;
• Having signed the informed consent form voluntarity before participating in the study.

LACTATING WOMEN:

• Healthy women presenting at their day 42±7 post-natal visit;
• 18-40 years of age;
• Monocyesis;
• Having signed the informed consent form voluntarily before participating in the study

Exclusion Criteria:

• Administration of DHA supplements (milk powder for pregnant women, DHA soft capsule, Zmarto, NURIZ, Naturies, HeadDHA, Beibeicong, Nutrimed etc);
• Still experiencing severe vomiting after 16 weeks of pregnancy;
• Women who have heart, liver, kidney, (ALT and AST≥ 1.5 times of normal upper limit, Cr>normal upper limit) or severe lung disease or laboratory abnormality (i.e.lipid metabolism disorder) that may interfere with the interpretation of study results, as indicated in previous examinations;
• Pregnant woman currently participating in other clinical trials or who have participated in another clinical trial in the last 30 days;
• Women who in the judgement of the investigator cannot be expected to comply with the protocol or study procedures.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To evaluate the feasibility in using DHA Screener for determination of internal DHA concentration	Correlation between DHA Screener and DHA concentration in plasma; Correlation between DHA Screener and DHA concentration in erythrocyte membrane; Correlation between DHA Screener and DHA concentration in breast milk.	5 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To compare the correlation between DHA Screener and RBC DHA among different subgroups. To compare DHA intake assessed by DHA Screener against Chinese recommendations of DHA intake.	To assess correlation between DHA Screener assessment tool and RBC DHA among study groups;; To compare DHA intake assessed by DHA Screener against Chinese recommendations of DHA intake.	5 months
To compare DHA intake assessed by DHA Screener against Chinese recommendations of DHA intake.	To compare DHA intake assessed by DHA Screener against Chinese recommendations of DHA intake.	5 months

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
To assess the correlation between DHA intake and DHA concentrations in the blood and breast milk of lactating women	To assess the correlation between DHA intake and DHA concentrations in the blood and breast milk of lactating women	5 months

Collaborators and Investigators

• Sponsor: Peking University
• Investigators: Study Chair: Jianmeng Liu, Doctor, Peking University

Study record dates

Study Major Dates

• Study Start: April 1, 2014
• Primary Completion (Actual): October 1, 2014
• Study Completion (Actual): October 1, 2014

Study Registration Dates

• First Submitted: April 1, 2014
• First Submitted That Met QC Criteria: April 1, 2014
• First Posted (Estimate): April 4, 2014

Study Record Updates

• Last Update Posted (Estimate): December 2, 2014
• Last Update Submitted That Met QC Criteria: December 1, 2014
• Last Verified: December 1, 2014

More Information

Terms related to this study

• Keywords: DHA intake;; Plasma;; Erythrocyte;; Breast milk.
• Other Study ID Numbers: 14.10.CN.INF